BillionToOne, Inc. income statement BLLN

In fiscal 2025, which ended Dec 31, 2025, BillionToOne, Inc. reported revenue of $305.1 million. Net income was $7.5 million, a profit margin of 2.4%. Operating income came to $16.0 million, an operating margin of 5.3%. Diluted earnings per share were $0.14. Over the twelve months ended Sep 30, 2026, revenue was $436.9 million and net income was $49.4 million.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

Line
FY 2026
Sep 30, 2026
FY 2025
Dec 31, 2025
Revenue
437
305
Cost of revenue
125
97
Gross profit
312
208
Research and development
66
49
Selling, general and administrative
201
143
Operating expenses
267
192
Operating income
45
16
Other income (expense)
5
-8
Pretax income
50
8
Income tax
0
0
Net income
49
7
Net income to common
46
3
Basic EPS
1.07
0.18
Diluted EPS
0.92
0.14
Weighted average shares, basic
43
16
Weighted average shares, diluted
50
21
Other measures
Depreciation and amortization
7
7
EBITDA
52
23
Interest coverage
1,655.26x
168.66x
Margins
Gross margin
71.41%
68.32%
Operating margin
10.23%
5.25%
Pretax margin
11.38%
2.54%
Profit margin
11.31%
2.44%
EBITDA margin
11.88%
7.51%
Effective tax rate
0.65%
3.93%
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.

Company profile

Industry
Services-Medical Laboratories (SIC 8071)
Listed as
BLLN (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Menlo Park, CA
SEC filer status
Non-accelerated filer, Emerging growth company
SEC CIK
2070849

Other Services-Medical Laboratories companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.